Fragile X Syndrome

About this condition

Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and the most common single-gene cause of autism spectrum disorder. Prevalence is approximately 1 in 4,000 males and 1 in 8,000 females. FXS is caused by a CGG trinucleotide repeat expansion in the 5' untranslated region of the FMR1 gene. Normal alleles have 5–44 repeats; premutation alleles have 55–200 repeats; full mutation alleles have more than 200 repeats, which triggers hypermethylation and gene silencing. Inheritance is X-linked, meaning affected males are typically more severely symptomatic (intellectual disability, behavioral issues, characteristic facial features, macroorchidism) while affected females have more variable and milder phenotypes due to random X-inactivation.

Premutation carriers are at risk for distinct conditions: fragile X-associated tremor/ataxia syndrome (FXTAS) — progressive neurodegeneration primarily affecting older males — and fragile X-associated primary ovarian insufficiency (FXPOI), occurring in approximately 20% of female premutation carriers and affecting fertility. The CGG repeat exhibits unstable inheritance: premutation alleles (55–200 repeats) undergo expansion during maternal meiosis and can expand to full mutation in a single generation. Maternal repeat length correlates with expansion risk: mothers carrying higher repeat counts have higher probability of transmitting a full mutation to offspring.

A confirmed FMR1 full mutation diagnosis enables early intervention services (speech, occupational, behavioral therapy from infancy), targeted pharmacotherapy for associated anxiety and ADHD, and educational planning informed by intellectual disability severity. It enables cascade testing of female relatives — identifying premutation carriers at risk for FXTAS (progressive neurodegeneration) and FXPOI (premature menopause affecting fertility planning). Preconception carrier screening for FMR1 premutation is now recommended by ACOG for all women considering pregnancy. Genetic counseling guides prenatal diagnosis options and family planning decisions.

Fragile X has two distinct clinical presentations: full mutation (FXS with intellectual disability) and premutation carriers (who may develop FXTAS or FXPOI without FXS).

Gene locus: FMR1 (Xq27.3) — CGG trinucleotide repeat

Standard short-read sequencing cannot detect CGG repeat expansions. Fragile X is systematically missed unless specifically tested.

Standard WGS cannot detect CGG trinucleotide repeats — Fragile X is invisible on most genetic tests

Standard short-read exome and genome sequencing universally FAIL at detecting CGG repeat expansions in FMR1. The repetitive nature of the region causes sequencing reads to fail or collapse, making the repeat invisible to standard bioinformatic pipelines. Fragile X testing has historically required specialized molecular methods: PCR-based repeat sizing followed by Southern blot analysis for methylation status. This means Fragile X is systematically missed by standard next-generation sequencing panels and even many 'comprehensive' genetic tests unless Fragile X-specific testing is explicitly ordered. Long-read sequencing technologies (PacBio, Oxford Nanopore) now enable repeat expansion detection from WGS data, but this requires specialized analytical pipelines and Dante Labs must confirm their capability.

Early testing identifies full mutation cases and premutation carriers — enabling prevention of transmission

A confirmed FMR1 full mutation diagnosis guides early intervention services (speech, occupational, behavioral therapy from infancy), enabling optimal neurodevelopmental outcomes with early support. Carrier testing of female relatives identifies premutation carriers who are at risk for FXTAS (progressive neurodegeneration), FXPOI (premature menopause and fertility planning), and transmission of full mutation to offspring. Preconception carrier screening is now ACOG-recommended for all women considering pregnancy. Prenatal diagnosis via CVS or amniocentesis is available for at-risk pregnancies. Genetic diagnosis connects families to the robust Fragile X research community and emerging therapies including gene therapy approaches in development.

Your son's mind works differently, learns differently — and you've been searching for the explanation. It's written in a repeated sequence of three letters.